International Ophthalmology

, Volume 38, Issue 1, pp 313–321 | Cite as

Extended targeted retinal photocoagulation versus conventional pan-retinal photocoagulation for proliferative diabetic retinopathy in a randomized clinical trial

  • Homayoun Nikkhah
  • Hossein Ghazi
  • Mohammad Reza Razzaghi
  • Saeed Karimi
  • Alireza Ramezani
  • Masoud Soheilian
Original Paper

Abstract

Purpose

To determine the clinical efficacy of extended targeted retinal photocoagulation (ETRP) compared to conventional panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy (PDR).

Methods

In a single-masked randomized clinical trial, 270 eyes of 234 patients with naïve early or high-risk PDR were randomly assigned to receive either CPRP or ETRP (135 eyes, each treatment arm). Best-corrected visual acuity (BCVA) measurement, fundus examination, wide-field fluorescein angiography (WFFA) and optical coherence tomography were carried out before and 3 months after retinal photocoagulation. Primary outcome was early PDR regression, specified as reduction in retinal neovascularization based on WFFA at 3 months. Secondary outcomes were BCVA and central macular thickness (CMT) changes.

Results

There were significantly more high-risk PDR eyes in ETRP group compared to CPRP (109 and 94 eyes, respectively, P = 0.04). Early PDR regression occurred in 71.9 and 64.4% of eyes in the ETRP and CPRP groups, respectively (P = 0.19). The mean number of applied laser spots in the ETRP was significantly fewer than CPRP (1202 vs. 1360, respectively, P < 0.001). Mean BCVA at baseline and 3 months post-laser were 0.37 ± 0.26 and 0.47 ± 0.19 logMAR in the ETRP arm, respectively. In the CPRP arm these values were 0.40 ± 0.27 and 0.47 ± 0.24 logMAR, respectively. Although mean BCVA decreased significantly in both treatment arms (ETRP P < 0.001, CPRP P = 0.009), the difference was not significant between arms (P = 0.68). CMT increased significantly in both groups (ETRP 41.08 μm, P < 0.001, CPRP 33.31 μm, P < 0.001). Nevertheless, the difference between the groups was not significant (P = 0.26).

Conclusions

ETRP with fewer number of laser spots may be an appropriate alternative to CPRP in PDR regression at least through 3 months.

Clinical trial.gov registration number

NCT01232179.

Keywords

Extended targeted retinal photocoagulation Panretinal photocoagulation Proliferative diabetic retinopathy 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no financial interest in the subject matter or materials discussed in this manuscript.

Ethical approval

The study was carried out after receiving the approval of the research ethics committee of Shahid Beheshti University of Medical Sciences and followed the tenets of the Declaration of Helsinki.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Beetham WP, Aiello LM, Balodimos MC, Koncz L (1969) Ruby-laser photocoagulation of early diabetic neovascular retinopathy: preliminary report of a long-term controlled study. Trans Am Ophthalmol Soc 67:39–67PubMedCentralPubMedGoogle Scholar
  2. 2.
    Pascolini D, Mariotti SP (2010) Global estimates of visual impairments: 2010. Br J Ophthalmol 96:614–618CrossRefGoogle Scholar
  3. 3.
    Diabetic Retinopathy Study Research Group (1976) Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 81:383–396CrossRefGoogle Scholar
  4. 4.
    Diabetic Retinopathy Study Research Group (1981) Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 88:583–600CrossRefGoogle Scholar
  5. 5.
    Early Treatment Diabetic Retinopathy Study Research Group (1991) Early photocoagulation for diabetic retinopathy, ETDRS report number 9. Ophthalmology 98(5 Suppl):766–785Google Scholar
  6. 6.
    Fong DS, Girach A, Boney A (2007) Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina 27:816–824CrossRefPubMedGoogle Scholar
  7. 7.
    Rand LI, Prud’homme GJ, Ederer F, Canner PL (1985) Factors influencing the development of visual loss in advanced diabetic retinopathy, Diabetic Retinopathy Study (DRS) report no. 10. Invest Ophthalmol Vis Sci 26:983–991PubMedGoogle Scholar
  8. 8.
    Watanachai N, Choovuthayakorn J, Patikulsila D, Ittipunkul N (2015) Changes in central macular thickness following single session multispot panretinal photocoagulation. J Ophthalmol. doi: 10.1155/2015/529529 PubMedCentralPubMedGoogle Scholar
  9. 9.
    Kaiser RS, Maguire MG, Grunwald JELD et al (2000) One-year outcomes of panretinal photocoagulation in proliferative diabetic retinopathy. Am J Ophthalmol 129:178–185CrossRefPubMedGoogle Scholar
  10. 10.
    Blankenship GW (1988) A clinical comparison of central and peripheral argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology 95:170–177CrossRefPubMedGoogle Scholar
  11. 11.
    Muqit MM, Marcellino GR, Henson DB et al (2013) Optos-guided pattern scan laser (Pascal)-targeted retinal photocoagulation in proliferative diabetic retinopathy. Acta Ophthalmol 91:251–258CrossRefPubMedGoogle Scholar
  12. 12.
    Japanese Society of Ophthalmic Diabetology, Subcommittee on the Study of Diabetic Retinopathy Treatment (2012) Multicenter randomized clinical trial of retinal photocoagulation for preproliferative diabetic retinopathy. Jpn J Ophthalmol 56:52–59CrossRefGoogle Scholar
  13. 13.
    Muqit MM, Young LB, McKenzie R et al (2013) Pilot randomised clinical trial of Pascal TargETEd Retinal versus variable fluence PANretinal 20 ms laser in diabetic retinopathy: PETER PAN study. Br J Ophthalmol 97:220–227CrossRefPubMedGoogle Scholar
  14. 14.
    Plumb AP, Swan AV, Chignell AH, Shilling JS (1982) A comparative trial of xenon arc and argon laser photocoagulation in the treatment of proliferative diabetic retinopathy. Br J Ophthalmol 66:213–218CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Reddy S, Hu A, Schwartz SD (2009) Ultra-wide field fluorescein angiography guided targeted retinal photocoagulation (TRP). Semin Ophthalmol 24:9–14CrossRefPubMedGoogle Scholar
  16. 16.
    Vine AK (1985) The efficacy of additional argon laser photocoagulation for persistent, severe proliferative diabetic retinopathy. Ophthalmology 92:1532–1537CrossRefPubMedGoogle Scholar
  17. 17.
    Okun E (1968) The effectiveness of photocoagulation in the therapy of proliferative diabetic retinopathy (PDR). (A controlled study in 50 patients). Trans Am Acad Ophthalmol Otolaryngol 72:246–252PubMedGoogle Scholar
  18. 18.
    Diabetic Retinopathy Study Research Group (1978) Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 85:82–106CrossRefGoogle Scholar
  19. 19.
    Osaadon P, Fagan XJ, Lifshitz T, Levy J (2014) A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye 28:510–520CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Writing Committee for the Diabetic Retinopathy Clinical Research Network (2015) Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314:2137–2146CrossRefGoogle Scholar
  21. 21.
    Sl Fine, Patz A (1987) Ten years after the diabetic retinopathy study. Ophthalmology 94:739–740CrossRefGoogle Scholar
  22. 22.
    Asher R, Hunt S, Hamilton AM et al (1981) Photocoagulation for optic disc new vessels in diabetes mellitus. Int Ophthalmol 3:79–85CrossRefPubMedGoogle Scholar
  23. 23.
    Lim AS, Khoo CY, Ang BC, Chiang C (1985) Argon laser photocoagulation in diabetic retinopathy: five-year review of 697 treated eyes. Ann Acad Med Singapore 14:252–260PubMedGoogle Scholar
  24. 24.
    Bailey CC, Sparrow JM, Grey RH, Cheng H (1999) The national diabetic retinopathy laser treatment audit. III. Clinical outcomes. Eye 13:151–159CrossRefPubMedGoogle Scholar
  25. 25.
    McDonald HR, Schatz H (1985) Macular edema following panretinal photocoagulation. Retina 5:5–10CrossRefPubMedGoogle Scholar
  26. 26.
    Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP (2009) Metabolic control and diabetic retinopathy. Curr Diabetes Rev 5:3–7CrossRefPubMedGoogle Scholar
  27. 27.
    Rema M, Sujatha P, Pradeepa R (2005) Visual outcomes of pan-retinal photocoagulation in diabetic retinopathy at one-year follow-up and associated risk factors. Indian J Ophthalmol 53:93–99CrossRefPubMedGoogle Scholar
  28. 28.
    Davis MD, Fisher MR, Gangnon RE et al (1998) Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early treatment diabetic retinopathy study report #18. Invest Ophthalmol Vis Sci 39:233–252PubMedGoogle Scholar
  29. 29.
    Shimura M, Yasuda K, Nakazawa T et al (2009) Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefe’s Arch Clin Exp Ophthalmol 247:1617–1624CrossRefGoogle Scholar
  30. 30.
    Soman M, Ganekal S, Nair U, Nair KGR (2012) Effect of panretinal photocoagulation on macular morphology and thickness in eyes with proliferative diabetic retinopathy without clinically significant macular edema. Clin Ophthalmol 6:2013–2017PubMedCentralPubMedGoogle Scholar
  31. 31.
    Brucker AJ, Qin H, Antoszyk AN et al (2009) Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol 127:132–140CrossRefPubMedGoogle Scholar
  32. 32.
    Singh RP, Habbu K, Ehlers JP et al (2016) The impact of systemic factors on clinical response to ranibizumab for diabetic maculae edema. Ophthalmology 123:1581–1587CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  • Homayoun Nikkhah
    • 2
  • Hossein Ghazi
    • 1
  • Mohammad Reza Razzaghi
    • 1
  • Saeed Karimi
    • 1
  • Alireza Ramezani
    • 2
  • Masoud Soheilian
    • 1
  1. 1.Ophthalmology Department and Ophthalmic Research CenterShahid Beheshti University of Medical SciencesTehranIran
  2. 2.Torfe and Imam Hossein medical centersShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations